Tagrisso
AstraZeneca’s Tagrisso beats standard of care in halting NSCLC
September 11, 2017Research and Development, Sales and Marketing AstraZeneca, ESMO, NSCLC, Tagrisso, non-small cell cell cancer, pharma, pharmaceutical
AstraZeneca has revealed new data at the European Society of Medical Oncology (ESMO) on the efficacy of Tagrisso (osimertinib) in …
AZ’s Tagrisso continues successes with EU approval
April 26, 2017Research and Development, Sales and Marketing AstraZeneca, EU, European Commission, NSCLC, Tagrisso
More good news for AstraZeneca’s Tagrisso (osimertinib), as the company announces that the European Commission has granted the drug full …
AstraZeneca ends month with two pieces of news
March 31, 2017Medical Communications, Sales and Marketing AstraZeneca, Tagrisso, TerSera Therapeutics, Zoladex
AstraZeneca has ended the month with more positive news on Tagrisso, that had previously been approved in China under its …
AstraZeneca’s medicine approved under China’s Priority Review
March 27, 2017Sales and Marketing AstraZeneca, Tagrisso, lung cancer
AstraZeneca has been boosted by the news that its drug, Tagrisso, has become its first drug to be approved under …
AZ lung cancer drug cuts disease progression by 70%
December 7, 2016Research and Development AstraZeneca, Tagrisso
AstraZeneca is touting its cancer drug Tagrisso (osimertinib) as a potential new standard of care for epidermal growth factor receptor …
AstraZeneca’s wins major drug approval by NICE
October 4, 2016Manufacturing and Production AstraZeneca, Cancer Drug Fund, NHS, Tagrisso
AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to …
Hanmi Pharma shares crash after shock contract termination
September 30, 2016Manufacturing and Production, Medical Communications, Research and Development Boehringer Ingelheim, Genentech, Germany, HM61713, Hanmi Pharmaceutical, Tagrisso, south korea
News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …
AstraZeneca presents positive Phase III results for lung cancer drug Tagrisso
July 18, 2016Manufacturing and Production, Research and Development AstraZeneca, Tagrisso
AstraZeneca has presented results from the latest Phase III trial evaluating Tagrisso (osimertinib) as a second line treatment for patients …
Chi-Med to get $10 million milestone from AstraZeneca after initiation of expanded Phase II trials in NSCLC
June 20, 2016Research and Development, Sales and Marketing AstraZeneca, Chi-Med, Iressa, Tagrisso, drug trial, lung cancer
Hutchison China MediTech (Nasdaq: HCM) on Monday said it is expanding Phase II trials in non-small cell lung cancer to …
Japanese approval for AZ lung cancer drug
March 29, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Tagrisso, lung cancer
AstraZeneca’s Tagrisso (osimertinib) has been approved in Japan for the treatment of a specific form of clung cancer. Japanese regulator, …
AstraZeneca’s Tagrisso gets EU lung cancer sign-off
February 4, 2016Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib
The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …
AstraZeneca earns ‘speedy’ FDA approval for lung cancer drug
November 13, 2015AZD9291, AstraZeneca, Tagrisso, lung cancer
The FDA has approved AstraZeneca’s new lung cancer drug Tagrisso, in a record two and half years from development, under …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
